Lu-Dendrimer Conjugated to Folate and Bombesin with Gold Nanoparticles in the Dendritic Cavity: A Potential Theranostic Radiopharmaceutical
Lu-Dendrimer Conjugated to Folate and Bombesin with Gold Nanoparticles in the Dendritic Cavity: A Potential Theranostic Radiopharmaceutical
复制标题
DOI:
--
复制
发表时间:
2016
期刊:
影响因子:
--
通讯作者:
Héctor Mendoza-Nava;G. Ferro-Flores;F. D. Ramírez;B. Ocampo-García;C. Santos-Cuevas;Liliana Aranda-Lara;E. Azorín-Vega;E. Morales-Ávila;K. Isaac-Olivé
中科院分区:
文献类型:
--
作者:
Héctor Mendoza-Nava;G. Ferro-Flores;F. D. Ramírez;B. Ocampo-García;C. Santos-Cuevas;Liliana Aranda-Lara;E. Azorín-Vega;E. Morales-Ávila;K. Isaac-Olivé
Lu-labeled nanoparticles conjugated to biomolecules have been proposed as a new class of theranostic radiopharmaceuticals. The aim of this research was to synthesize Lu-dendrimer(PAMAM-G4)-folate-bombesin with gold nanoparticles (AuNPs) in the dendritic cavity and to evaluate the radiopharmaceutical potential for targeted radiotherapy and the simultaneous detection of folate receptors (FRs) and gastrin-releasing peptide receptors (GRPRs) overexpressed in breast cancer cells. p-SCN-Benzyl-DOTA was conjugated in aqueous-basic medium to the dendrimer. The carboxylate groups of LysLys(DOTA)-bombesin and folic acid were activatedwithHATUand also conjugated to the dendrimer.The conjugatewasmixedwith 1%HAuCl 4 followed by the addition of NaBH 4 and purified by ultrafiltration. Elemental analysis (EDS), particle size distribution (DLS), TEM analysis, UV-Vis, and infrared and fluorescence spectroscopies were performed. The conjugate was radiolabeled using LuCl 3 or GaCl 3 and analyzed by radio-HPLC. Studies confirmed the dendrimer functionalization with high radiochemical purity (>95%). Fluorescence results demonstrated that the presence of AuNPs in the dendritic cavity confers useful photophysical properties to the radiopharmaceutical for optical imaging. Preliminary binding studies in T47D breast cancer cells showed a specific cell uptake (41.15 ± 2.72%). Ludendrimer(AuNP)-folate-bombesin may be useful as an optical and nuclear imaging agent for breast tumors overexpressing GRPR and FRs, as well as for targeted radiotherapy.